DANCANN PHARMA A/S

DANCANN PHARMA A/S (CVR number: 39426005K) is a company from VARDE. The company reported a net sales of 6.1 mDKK in 2023, demonstrating a growth of 6.4 % compared to the previous year. The operating profit percentage was poor at -989.9 % (EBIT: -60.1 mDKK), while net earnings were -62.3 mDKK. The profitability of the company measured by Return on Assets (ROA) was -131.5 %, which can be considered poor and Return on Equity (ROE) was -172.2 %, which can be considered poor. The equity ratio, a key indicator for solidity, stood at 54.7 %, a level that can be considered to be modest. This means a balanced mix of debt and equity financing its assets—a typical operational level for many companies. DANCANN PHARMA A/S's liquidity measured by quick ratio was 0.4 which is at a very low level. Thus, the company is in an unstable financial position, with its liquid assets significantly undermatching its current liabilities. This severe liquidity deficiency may lead to financial distress and threaten the company's operational continuity.